arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Mineralys Therapeutics, Inc.

MLYS

$27.34 ▲ +0.37 (+1.37%) at close

18 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Mineralys Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -5.6% ↘

FCF / Share $-0.48

Trailing P/E —

Price / Book 3.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-39.34M

↑ +6.8% —

FCF / Share Free cash flow per share

$-0.48

↑ +44.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	40.5% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	64.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	54.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	20.5% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-12.9% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-55.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-98.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-167.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-37.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	64.0% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	55.8% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	75.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	65.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	6.8% Fair ↑ Fair Improving Year-over-year change in net income	34.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-34.0% Weak ↑ Weak Improving Year-over-year change in net income	-34.0% Weak ↑ Weak Improving Year-over-year change in net income	-34.0% Weak ↑ Weak Improving Year-over-year change in net income	-100.7% Weak ↑ Weak Improving Year-over-year change in net income	-149.9% Weak → Weak Stable Year-over-year change in net income	-149.9% Weak ↓ Weak Declining Year-over-year change in net income	-149.9% Weak ↓ Weak Declining Year-over-year change in net income	-168.8% Weak ↓ Weak Declining Year-over-year change in net income	-66.6% Weak → Weak Stable Year-over-year change in net income	-66.6% Weak Weak Year-over-year change in net income	-66.6% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	44.3% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-100.7% Weak Weak Year-over-year change in free cash flow	—	—	—	17.4% Good Good Year-over-year change in free cash flow	—	—	—	59.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
FCF / Net Income (x)	1.00x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.18x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.37x Good Good Free cash flow relative to reported net income Optimal: > 1x	—	—	0.61x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.12x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-5.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-4.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-5.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-11.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-10.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-21.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	15.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	13.5% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	13.9% Good Good Return earned on debt + equity capital invested Optimal: > 10%	26.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-6.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-5.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-22.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-14.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-4.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-8.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-6.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-141%)	-5.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-133%)	-7.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-149%)	-13.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-190%)	-12.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-182%)	-25.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-271%)	-13.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-189%)	-10.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-172%)	-9.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-164%)	-10.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-167%)	-4.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-132%)	-4.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-129%)	-4.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-128%)	17.4% Good ↓ Good Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+16%)	17.4% Good ↓ Good Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+16%)	20.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+37%)	33.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+120%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Net Debt (USD)	$-112.78M	$-172.92M	$-217.60M	$-101.79M	$-165.01M	$-114.09M	$-97.27M	$-67.86M	$-90.42M	$-49.30M	$-86.30M	$-101.14M	$-138.25M	$-87.70M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-0.47	$-0.35	$-0.52	$-0.66	$-0.79	$-0.98	$-1.13	$-0.83	$-0.70	$-0.63	$-0.57	$-0.31	$-0.51	$-1.75	$-1.29	$-1.26	$-1.48	—
Free Cash Flow per Share (USD)	$-0.48	—	$-0.41	$-0.46	$-0.86	—	—	—	$-0.43	—	—	—	$-0.52	—	$-1.35	$-1.06	$-1.28	—
Book Value per Share (USD)	$7.74	$7.93	$7.30	$4.77	$5.26	$3.84	$4.76	$5.84	$6.61	$5.86	$6.42	$6.98	$7.24	$-8.14	$-8.38	$-7.17	$-4.47	—
Tangible Book Value per Share (USD)	$7.74	$7.93	$7.30	$4.77	$5.26	$3.84	$4.76	$5.84	$6.61	$5.86	$6.42	$6.98	$7.24	$-8.14	$-8.38	$-7.17	$-4.47	—
Basic Weighted Avg Shares (shares)	82.83M	—	70.59M	65.45M	53.16M	—	49.82M	49.36M	44.90M	—	39.93M	39.75M	24.76M	—	5.18M	5.15M	5.12M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$637.75M	$646.27M	$576.28M	$313.10M	$341.12M	$190.71M	$236.41M	$289.60M	$327.62M	$238.62M	$251.83M	$263.28M	$264.71M	$104.74M	—	—	—	—
Total Equity (USD)	$638.14M	$646.69M	$576.43M	$313.55M	$341.56M	$191.26M	$236.93M	$290.10M	$328.05M	$241.15M	$264.01M	$285.01M	$295.88M	$-52.27M	$-43.41M	$-36.93M	$-22.93M	$-22.93M

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Depreciation Expense (USD)	$6.00K	$13.00K	$15.00K	$16.00K	$15.00K	$15.00K	—	—	$8.00K	$0.00	—	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-39.34M	$-32.23M	$-42.21M	$-42.21M	$-42.21M	$-48.95M	$-31.51M	$-31.51M	$-31.51M	$-24.39M	$-12.61M	$-12.61M	$-12.61M	$-9.07M	$-7.57M	$-7.57M	$-7.57M	—
Operating Cash Flow (USD)	$-39.47M	$-37.89M	$-28.87M	$-30.17M	$-45.49M	$-66.84M	—	—	$-19.14M	$-28.98M	—	—	$-12.78M	$-10.19M	$-6.99M	$-5.47M	$-6.58M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters

Mineralys Therapeutics, Inc.

Analytical Summary

18-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MLYS with peers